A Medicare advisory panel could not find adequate evidence to conclude that beta amyloid positron emission tomography imaging of brain beta amyloid changes health outcomes in patients who display early symptoms or signs of cognitive dysfunction.
CMS convened the Medicare Evidence Development and Coverage Advisory Committee at its Baltimore headquarters on Jan. 30 to review the available evidence on beta amyloid PET imaging for the management...